Tobacco Product Use Among Adults — United States, 2019
By M. Cornelius, Teresa W. Wang, Ahmed Jamal, Caitlin G. Loretan, L. Neff. MMWR. Morbidity and mortality weekly report, 2020
986 citations recorded by the source corpus.
Cigarette smoking remains the leading cause of preventable disease and death in the United States (1). The prevalence of current cigarette smoking among U.S. adults has declined over the past several decades, with a prevalence of 13.7% in 2018 (2). However, a variety of combustible, noncombustible, and electronic tobacco products are available in the United States (1,3). To assess recent national estimates of tobacco product use among U.S. adults aged ≥18 years, CDC analyzed data from the 2019 National Health Interview Survey (NHIS). In 2019, an estimated 50.6 million U.S. adults (20.8%) reported currently using any tobacco product, including cigarettes (14.0%), e-cigarettes (4.5%), cigars (3.6%), smokeless tobacco (2.4%), and pipes* (1.0%).† Most current tobacco product users (80.5%) reported using combustible products (cigarettes, cigars, or pipes), and 18.6% reported using two or more tobacco products.§ The prevalence of any current tobacco product use was higher among males; adults aged ≤65 years; non-Hispanic American Indian/Alaska Native (AI/AN) adults; those whose highest level of educational attainment was a General Educational Development (GED) certificate; those with an annual household income <$35,000; lesbian, gay, or bisexual (LGB) adults; uninsured adults and those with Medicaid; those with a disability; or those with mild, moderate, or severe generalized anxiety disorder. E-cigarette use was highest among adults aged 18-24 years (9.3%), with over half (56.0%) of these young adults reporting that they had never smoked cigarettes. Implementing comprehensive, evidence-based, population level interventions (e.g., tobacco price increases, comprehensive smoke-free policies, high-impact antitobacco media campaigns, and barrier-free cessation coverage), in coordination with regulation of the manufacturing, marketing, and sale of all tobacco products, can reduce tobacco-related disease and death in the United States (1,4). As part of a comprehensive approach, targeted interventions are also warranted to reach subpopulations with the highest prevalence of use, which might vary by tobacco product type.
Subfields: Applied Psychology, Physiology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/d3e63950eec7de183779702151a7d7f8279953fa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
In Public Health, Environmental and Occupational Health
Citations in the corpus
- Annual report to the nation on the status of cancer, part 1: National cancer statistics (2022, positive): “Adult smoking prevalence declined from >40% during the early 1960s to 13% in 2019.(26,27) The decline in lung cancer death rates during the most recent period, however, was more than double the decline for incidence, in part reflecting recent advances in targeted and immune therapies for non‐small c”
- Tobacco Product Use Among Adults — United States, 2017 (2018, background): “Efforts to strengthen household financial security; stabilize housing; teach youths coping and problemsolving skills; identify and support persons at risk; and implement proactive prevention policies in schools, workplaces, and other organizational settings are associated with reductions in MMWR / N”